Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Moderna Inc (NASDAQ: MRNA) was $119.22 for the day, up 0.32% from the previous closing price of $118.84. In other words, the price has increased by $0.32 from its previous closing price. On the day, 3.11 million shares were traded. MRNA stock price reached its highest trading level at $122.45 during the session, while it also had its lowest trading level at $118.1.
Ratios:
Our analysis of MRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.91 and its Current Ratio is at 4.03. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 31 ’24 when NOUBAR B AFEYAN bought 15,000 shares for $118.84 per share.
AFEYAN NOUBAR sold 15,000 shares of MRNA for $1,766,972 on Jul 24 ’24. The Director now owns 2,239,015 shares after completing the transaction at $117.80 per share. On Jul 17 ’24, another insider, AFEYAN NOUBAR, who serves as the Director of the company, sold 15,000 shares for $122.84 each. As a result, the insider received 1,842,651 and left with 2,254,015 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 46970056704 and an Enterprise Value of 38258208768. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.88 while its Price-to-Book (P/B) ratio in mrq is 3.56. Its current Enterprise Value per Revenue stands at 7.424 whereas that against EBITDA is -8.39.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is -10.85%, while the 200-Day Moving Average is calculated to be 12.93%.
Shares Statistics:
MRNA traded an average of 3.92M shares per day over the past three months and 2349850 shares per day over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 336.78M. Insiders hold about 12.12% of the company’s shares, while institutions hold 66.75% stake in the company. Shares short for MRNA as of 1721001600 were 22738949 with a Short Ratio of 5.80, compared to 1718323200 on 21604553. Therefore, it implies a Short% of Shares Outstanding of 22738949 and a Short% of Float of 7.8099996.
